JNJ-26854165 (Serdemetan)

Name: JNJ-26854165 (Serdemetan)
Brand: Selleck Chemicals
SKU: S1172
Rating: 5 (11 reviews)

For research use only.

Catalog No.S1172

11 publications

JNJ-26854165 (Serdemetan) Chemical Structure

CAS No. 881202-45-5

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Selleck's JNJ-26854165 (Serdemetan) has been cited by 11 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Res, 2020, canres.3499.2019

PubMed: 33372039 ( click the link to review the publication )

Circulation, 2020, 10.1161/CIRCULATIONAHA.120.048191

PubMed: 32755395 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7777-7790

PubMed: 27999193 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra98

PubMed: 27703031 ( click the link to review the publication )

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

Sci Rep, 2014, 4:4664

PubMed: 24722541 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	NGT0R45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVy2WXFzUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOUOyN\|Yh\|ryP	M4\TW3NCVkeHUh?=
H4 cell	NFuybJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYTl[JFFUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFY4ODdizszN	NWPPOJB6W0GQR1XS
KGN cell	M3fWSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF7pc\|FKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlIxPSEQvF2=	MX;TRW5ITVJ?
786-0 cell	NYPBbGxVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXTwNXA6UW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzJ7OEmg{txO	NUDqT\|hQW0GQR1XS
769-P cell	MmrxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWXJcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT64NlIzPCEQvF2=	NVfDXGFpW0GQR1XS
K5 cell	M13Femdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUDJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMU[yOEDPxE1?	MoX0V2FPT0WU
MLMA cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYjJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFMzOTdizszN	M1P5[XNCVkeHUh?=
MLMA cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlX1TY5pcWKrdHnvckBw\iCqdX3hckBOVE2DIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yPFcxOyEQvF2=	M1jGdXNCVkeHUh?=
EW-7 cell	M2[4bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{DpZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|I3QTVizszN	NH3XOI5USU6JRWK=
SW1088 cell	NUKxTmtqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnjCTY5pcWKrdHnvckBw\iCqdX3hckBUXzFyOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlgxPjVzIN88US=>	M1;NbXNCVkeHUh?=
MC-IXC cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYPJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFc4QTJizszN	NG\ZZVFUSU6JRWK=
NCI-H2052 cell	NIDnU3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIXlSZhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwMEixOVch\|ryP	MoTrV2FPT0WU
IGR-1 cell	NXriWXdwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX;6W3JxUW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO	M2rMTHNCVkeHUh?=
DSH1 cell	NYn3WYw6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWPWSWhNUW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDJ7NjFOwG0>	NXL4eog4W0GQR1XS
PA-1 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmfkTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6zNFA2Qc7:TR?=	NUnH[\|N4W0GQR1XS
SK-MEL-3 cell	M{ToSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHLnSHVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5\|MUKwO{DPxE1?	NHPTUYFUSU6JRWK=
SW900 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXPDcGFNUW6qaXLpeIlwdiCxZjDoeY1idiCVV{mwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDh{NUWg{txO	M3fES3NCVkeHUh?=
CAKI-1 cell	M3zqR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NU[zUFg5UW6qaXLpeIlwdiCxZjDoeY1idiCFQVvJMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV{N{O4JO69VQ>?	M{XMcnNCVkeHUh?=
ES1 cell	NX7nSGtFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mo[1TY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkWyPFk4KM7:TR?=	NIHMU\|FUSU6JRWK=
SK-N-DZ cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUjHUlExUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54MkW5OUDPxE1?	NGHHPIlUSU6JRWK=
RH-1 cell	NVLCO4VDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NG\LWZlKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ\|IN88US=>	NIjQV4NUSU6JRWK=
ES8 cell	NHTHU3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWrJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwNkm3NFIh\|ryP	Mm\4V2FPT0WU
NEC8 cell	MnjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lke2PVgzKM7:TR?=	NWPESJFLW0GQR1XS
LNCaP-Clone-FGC cell	MnO0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYTJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFM2OzZizszN	NXXtPINUW0GQR1XS
HCE-4 cell	NHrHb\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2XkNmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk5ODdizszN	M4HjSHNCVkeHUh?=
U-118-MG cell	NWi3UWdHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnfDTY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODFyNk[g{txO	Mo[zV2FPT0WU
GI-ME-N cell	NFPnOWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYnyflI3UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1?	M4\MV3NCVkeHUh?=
LB1047-RCC cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3HQUWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMU[xOFMh\|ryP	MXXTRW5ITVJ?
HT-1080 cell	NFrEbZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIG5PHFKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>?	MVjTRW5ITVJ?
NB69 cell	M2nXfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2P2cmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|UxPDdizszN	MXrTRW5ITVJ?
NCI-H1693 cell	M3e0VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn;FTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR2OEm1JO69VQ>?	MnqzV2FPT0WU
HSC-3 cell	NH[1dpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFk6OzNizszN	MWTTRW5ITVJ?
MDA-MB-231 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>?	NVzn[3c5W0GQR1XS
HOS cell	NEHUXnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NX7TSZdpUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN	MoWzV2FPT0WU
BT-549 cell	MnXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGJVNTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|g5PyEQvF2=	Mn3UV2FPT0WU
NB17 cell	NY\Md4FYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MoLKTY5pcWKrdHnvckBw\iCqdX3hckBPSjF5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND63PFk4PiEQvF2=	MoS5V2FPT0WU
5637 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2KwR2lvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|k3PTJizszN	M{P5NnNCVkeHUh?=
OVCAR-8 cell	Mn\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXLwT\|hsUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57MkSzOkDPxE1?	MUDTRW5ITVJ?
G-402 cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND65N\|A{PSEQvF2=	M{TnO3NCVkeHUh?=
BB30-HNC cell	M16zemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPzJzODFOwG0>	M3PnUnNCVkeHUh?=
HCC1806 cell	NWXuPXQyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWPiRW5vUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1?	Mk\qV2FPT0WU
COLO-800 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3q0dWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF{NkSg{txO	NEPyOGhUSU6JRWK=
FADU cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3TDTGlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|Y2PTdizszN	MUDTRW5ITVJ?
NCI-H1651 cell	NU\mWWVFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYXWXlVvUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkO5OFA6KM7:TR?=	MknBV2FPT0WU
AGS cell	NWnEXWsyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNEe3NVEh\|ryP	NXWzXGZsW0GQR1XS
CHP-212 cell	M1KxWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2TYemlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl2MEmg{txO	Mn\vV2FPT0WU
YAPC cell	NF3KWG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYrZUml1UW6qaXLpeIlwdiCxZjDoeY1idiC\QWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PzdzMTFOwG0>	MVrTRW5ITVJ?
GOTO cell	NUXPXpczT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn3pTY5pcWKrdHnvckBw\iCqdX3hckBIV1SRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60PVU4PiEQvF2=	MVLTRW5ITVJ?
KYSE-510 cell	M4\hW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXjJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OTFizszN	MoOxV2FPT0WU
NCI-H2342 cell	Ml3oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHy4VGxKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNUOyO\|gh\|ryP	NHfpdIhUSU6JRWK=
BFTC-905 cell	NUDLSFZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVKwZmx6UW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNkK4N\|Uh\|ryP	Mmj4V2FPT0WU
EW-16 cell	NUnxeph1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGHt[pRKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB7MzFOwG0>	NWq5R3p{W0GQR1XS
SK-MEL-30 cell	NFTKN5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2DKXGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS55NEW0N{DPxE1?	NYXPUJpWW0GQR1XS
HLE cell	NHu2OZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4K3e2lvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT63O\|Q5QSEQvF2=	MWLTRW5ITVJ?
T98G cell	M3zFTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYPsPYRMUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44QTZ\|NTFOwG0>	M4rsS3NCVkeHUh?=
HUTU-80 cell	NEWwcGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoXETY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45PDJ{ODFOwG0>	M4n3V3NCVkeHUh?=
NOS-1 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnewTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVQ4PjZizszN	M2HLN3NCVkeHUh?=
SW780 cell	NFLKVW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHL6eW9KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46Pjl2OTFOwG0>	NF7QO5dUSU6JRWK=
KYSE-180 cell	MofDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3TpVWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl5NkW0JO69VQ>?	M1rJ[nNCVkeHUh?=
MDA-MB-361 cell	NH3SOm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl6NkS3JO69VQ>?	M{HWbnNCVkeHUh?=
SNU-C2B cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS2FMlKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlAyOTN6IN88US=>	M1ziZXNCVkeHUh?=
NCI-H661 cell	NYm4NJZHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNk[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xPjl2IN88US=>	MnfrV2FPT0WU
OE33 cell	M1jOcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{jnRWlvcGmkaYTpc44hd2ZiaIXtZY4hV0V\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNVQ{QDlizszN	M3LyN3NCVkeHUh?=
TYK-nu cell	NID4TI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mny3TY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ\|IN88US=>	MY\TRW5ITVJ?
COLO-792 cell	NIPGRm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYjJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0>	Mln3V2FPT0WU
HEL cell	Ml;IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2\je2lvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj6yOlc3KM7:TR?=	NHvGdZdUSU6JRWK=
D-566MG cell	NV;4OmppT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NV:xZVlRUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5\|M{S5NUDPxE1?	NIfwem9USU6JRWK=
U031 cell	M2ryS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkSxPFE3KM7:TR?=	MmjZV2FPT0WU
COR-L23 cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MoLpTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0>	MVzTRW5ITVJ?
NCI-H2452 cell	NHnybXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4HQbWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi53MkK4NUDPxE1?	M3XiVHNCVkeHUh?=
BB65-RCC cell	NV3Pcph3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFn4OJpKdmirYnn0bY9vKG:oIHj1cYFvKEKENkWtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi54NEW5JO69VQ>?	MlHzV2FPT0WU
CAL-33 cell	MkDGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MojTTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PjZ3IN88US=>	NYL2ZVVLW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p53 / HDM2 / HDMX / p21 / Noxa / Puma ; PubMed: 20736344 Mol Cancer Ther OCI-AML-3 and MOLM-13 cells were incubated with a range of concentrations of JNJ-26854165 for 18 hours. ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; PubMed: 23820125 J Pharmacol Exp Ther U266 and JeKo-1 cells were treated with JNJ-26854165 and cells harvested at the indicated time points. MDM2 / p-MDM2 / p53 ; PubMed: 27999193 Oncotarget K562 cells was harvested at 48 h after treatment with various JNJ-165 concentrations, and then nuclear and cytoplasmic extracts were prepared to check the levels of p53, MDM2 and p-MDM2 by Western blotting. Actin and LaminB were used as loading control respectively. Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 ; PubMed: 27999193 Oncotarget CML cell lines were treated with JNJ-165 at the indicated doses for 48 h. Whole-cell lysates were extracted to assess the levels of BCR-ABL and phosphorylated (p)-BCR-ABL (Tyr177), and then were analyzed for BCR-ABL downstream signaling mediators p-CrkL (Try207), total Stat5, p-Stat5 (Tyr694), total Stat3, and p-Stat3 (Ser727) expression by Western blot analysis. The expression of β-actin was used as loading control. The data are representative of three determinations with identical results.	20736344 23820125 27999193
Growth inhibition assay	Cell viability; PubMed: 23820125 J Pharmacol Exp Ther MCL (B) and MM (C) cell lines were seeded in 96-well plates for viability analyses using WST-1 and treated with JNJ-26854165 for 72 hours. Results are expressed as the percentage of cell viability in relation to the vehicle-treated sample for each cell line, which was arbitrarily set at 100%	23820125
Immunofluorescence	p53; PubMed: 27999193 Oncotarget Two-color fluorescence microscope analysis of antibody against p53 protein (green) and nuclei (DAPI staining, blue) showed nuclear accumulation of p53 in K562 cells with treatment of 1 μM JNJ-165, but not in control-treated cells after 48 h. Images were taken on a fluorescence microscopy (100×).	27999193

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: CB17SC scid^-/- female mice.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Ethanol	2 mg/mL (6.08 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes. Pifithrin-α is also a potent agonist of the aryl hydrocarbon receptor (AhR).
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also an inhibitor of dihydroorotate dehydrogenase (DHODH).
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity and inhibits dihydroorotate dehydrogenase (DHODH). Tenovin-6 is also an inhibitor of SirT1 and SirT2.
NSC 319726

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

Features:An allele-specific p53 mutant reactivator.
Pifithrin-μ

Pifithrin-μ (NSC 303580, PFTμ, 2-Phenylethynesulfonamide) is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK (Z-VAD(OH)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)